Related Experiment Video
Updated: May 23, 2026
07:24
Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
Testosterone supplementation in heart failure: a meta-analysis
Mustafa Toma1, Finlay A McAlister, Erin E Coglianese
1St Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
Circulation. Heart Failure
|April 19, 2012
Summary
Testosterone therapy significantly improved exercise capacity in men with heart failure (HF). This finding suggests a promising treatment option for enhancing functional ability in this patient group, with no observed adverse cardiovascular events.
Area of Science:
- Cardiology
- Endocrinology
- Exercise Physiology
Background:
- Low testosterone is linked to reduced exercise capacity and poor outcomes in heart failure (HF) patients.
- Stable chronic heart failure patients often experience diminished functional capacity.
Purpose of the Study:
- To evaluate if testosterone therapy enhances exercise capacity in stable chronic heart failure patients.
- To determine the efficacy of testosterone supplementation in improving physical function for heart failure individuals.
Main Methods:
- Systematic review and meta-analysis of randomized controlled trials (RCTs) published between 1980-2010.
- Included four RCTs with 198 male participants (mean age 67 years).
- Assessed exercise capacity using the 6-minute walk test, incremental shuttle walk test, and peak oxygen consumption.
Main Results:
- Testosterone therapy demonstrated a significant improvement in exercise capacity compared to placebo.
- Mean improvements observed: 54.0m in 6-minute walk test, 46.7m in incremental shuttle walk test, and 2.70 mL/kg/min in peak oxygen consumption.
- No significant adverse cardiovascular events were reported during the treatment period.
Conclusions:
- Testosterone therapy shows promise for improving functional capacity in heart failure patients.
- Further large-scale RCTs are needed to confirm benefits for quality of life, clinical events, and safety in this high-risk population.
More Related Videos
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...